Skip to content

The efficacy of melatonin for the prevention of taxane-induced peripheral neuropathy

Evaluating the effectiveness of melatonin for the prevention of taxane-induced peripheral neuropathy in patients with breast cancer: A double-blinded randomized clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160310026998N14
Enrollment
132
Registered
2023-04-11
Start date
2023-04-03
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Taxane-induced peripheral neuropathy in patients with breast cancer. benign neoplasm of breast

Interventions

Intervention 1: Intervention group: Patients will receive 15 mg of melatonin (3 tablets of melatonin 5 mg - JALINOUS Co.) daily at bedtime for 12 weeks. The first day of chemotherapy with taxanes will

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients with breast cancer who are candidate for chemotherapy with taxanes

Exclusion criteria

Exclusion criteria: History of neuropathy Use of medications that can cause neuropathy such as statins, colchicine, zidovudine, penicillamine, platinum derivatives (cisplatin, oxaliplatin), and vinca alkaloids History of fibromyalgia, rheumatoid arthritis, osteoarthritis, hypothyroidism, sleep apnea, autoimmune diseases, diabetes mellitus, heart failure, myocardial infarction, uncontrolled hypertension, unstable angina, stroke, and seizure in the previous year History of allergy to melatonin Alcohol intake Active infection (such as COVID-19 or other respiratory infections) History of prior chemotherapy Severe kidney or liver failure Presence of other malignancies Prediction of patient nonadherence

Design outcomes

Primary

MeasureTime frame
Frequency of peripheral neuropathy. Timepoint: At baseline, after 12-week intervention, and 3 months after intervention termination. Method of measurement: The Michigan Neuropathy Screening Instrument (MNSI), DN4 questionnaire, neurofilaments and Diapazone test.

Secondary

MeasureTime frame
Adverse effects of taxanes. Timepoint: At baseline, after the 12-week intervention, and 3 months after intervention termination. Method of measurement: The Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane) questionnaire.;Anxiety in patients. Timepoint: At baseline, after 12-week intervention, and 3 months after intervention termination. Method of measurement: PROMIS Emotional Distress – Anxiety – Short Form.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactsaba Ghaffary

Tabriz University of Medical Sciences

ghaffarys@tbzmed.ac.ir+98 41 3336 5010

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026